- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
FDA warns of seizure risk for multiple sclerosis patients who take dalfampridine
The FDA recently announced a safety communication regarding the risk of seizures with MS who are starting dalfampridine.
On July 23, 2012, FDA announced a safety communication regarding the risk of seizures in patients with multiple sclerosis (MS) starting dalfampridine (Ampyra). Ampyra was approved by FDA in 2010 to improve walking in patients with MS. The safety communication stemmed from a review of post-marketing adverse event reports.
Seizures are a known risk of dalfampridine therapy at the approved dose of 10 mg twice daily. According to FDA, most post-marketing cases occurred days to weeks after starting therapy and in patients with no known history of seizures. The risk of seizures increases with increasing drug concentrations and given that dalfampridine is cleared renally, patients with even mild renal impairment [creatinine clearance (CrCl) of 51 mL/min to 80 mL/min] can accumulate the drug to levels which may precipitate a seizure.
FDA reminds clinicians that mild renal impairment in patients over aged 50 years is common due to an age-associated decline in kidney function. For this reason, patients with a CrCl of 51 mL/min to 80 mL/min are considered to be at an increased risk of seizures. FDA warns clinicians to weigh the risks versus benefits of therapy carefully in the patient population.
"The risk of seizures on [dalfampridine] is not a new finding, however, this safety communication highlights the importance of appropriate patient selection for the use of dalfampridine, as well as proper monitoring," Diana Sobieraj, PharmD, assistant professor at the University of Connecticut School of Pharmacy, Storrs, Conn., told Formulary. "Patient education is also paramount since this is an extended-release formulation, patients should be aware that taking the tablet whole-and not trying to 'catch up' if they miss a dose-will help to assure proper drug concentrations."
SOURCES
1. FDA Drug Safety Communication: Seizure risk for multiple sclerosis patients who take Ampyra (dalfampridine) Available at: http://www.fda.gov/Drugs/DrugSafety/ucm312846.htm Accessed July 26, 2012.
2. Ampyra [package insert]. FDA. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022250s003s004lbl.pdf. Accessed July 26, 2012.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
